MX2022015818A - Uso de moléculas de unión del ligando 13 de quimiocina del motivo c-x-c (cxcl13) para el tratamiento de lesión de nervios periféricos. - Google Patents

Uso de moléculas de unión del ligando 13 de quimiocina del motivo c-x-c (cxcl13) para el tratamiento de lesión de nervios periféricos.

Info

Publication number
MX2022015818A
MX2022015818A MX2022015818A MX2022015818A MX2022015818A MX 2022015818 A MX2022015818 A MX 2022015818A MX 2022015818 A MX2022015818 A MX 2022015818A MX 2022015818 A MX2022015818 A MX 2022015818A MX 2022015818 A MX2022015818 A MX 2022015818A
Authority
MX
Mexico
Prior art keywords
peripheral nerve
binding molecules
nerve regeneration
cxcl13 binding
promote peripheral
Prior art date
Application number
MX2022015818A
Other languages
English (en)
Inventor
Simone Digiovanni
Luming Zhou
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of MX2022015818A publication Critical patent/MX2022015818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

En el presente documento se proporcionan métodos para promover la regeneración axonal de las neuronas sensoriales y la recuperación funcional de las neuronas después de una lesión del nervio periférico en un sujeto que experimenta una disminución regenerativa nerviosa dependiente del envejecimiento, comprendiendo el método administrar a un sujeto que lo necesita una cantidad eficaz de una molécula de unión aislada que se une específicamente a CXCL13.
MX2022015818A 2020-06-11 2021-06-08 Uso de moléculas de unión del ligando 13 de quimiocina del motivo c-x-c (cxcl13) para el tratamiento de lesión de nervios periféricos. MX2022015818A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063037755P 2020-06-11 2020-06-11
PCT/US2021/036298 WO2021252422A1 (en) 2020-06-11 2021-06-08 Use of cxcl13 binding molecules to promote peripheral nerve regeneration

Publications (1)

Publication Number Publication Date
MX2022015818A true MX2022015818A (es) 2023-03-28

Family

ID=76708469

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015818A MX2022015818A (es) 2020-06-11 2021-06-08 Uso de moléculas de unión del ligando 13 de quimiocina del motivo c-x-c (cxcl13) para el tratamiento de lesión de nervios periféricos.

Country Status (11)

Country Link
US (1) US11702470B2 (es)
EP (1) EP4164745A1 (es)
JP (1) JP2023530255A (es)
KR (1) KR20230021747A (es)
CN (1) CN116782930A (es)
AU (1) AU2021286476A1 (es)
BR (1) BR112022025230A2 (es)
CA (1) CA3181985A1 (es)
IL (1) IL298814A (es)
MX (1) MX2022015818A (es)
WO (1) WO2021252422A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3068180B2 (ja) 1990-01-12 2000-07-24 アブジェニックス インコーポレイテッド 異種抗体の生成
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US20080227704A1 (en) 2006-12-21 2008-09-18 Kamens Joanne S CXCL13 binding proteins
US20080199481A1 (en) 2007-02-21 2008-08-21 Astrazeneca Ab Compounds
CA2810217C (en) 2010-09-02 2019-03-12 Vaccinex, Inc. Anti-cxcl13 antibodies and methods of using the same
CA3098509A1 (en) 2018-09-18 2020-03-26 I-Mab Biopharma Us Limited Anti-cxcl13 antibodies for treating autoimmune diseases and cancer

Also Published As

Publication number Publication date
EP4164745A1 (en) 2023-04-19
BR112022025230A2 (pt) 2022-12-27
IL298814A (en) 2023-02-01
CN116782930A (zh) 2023-09-19
CA3181985A1 (en) 2021-12-16
AU2021286476A1 (en) 2023-02-02
JP2023530255A (ja) 2023-07-14
WO2021252422A1 (en) 2021-12-16
KR20230021747A (ko) 2023-02-14
US11702470B2 (en) 2023-07-18
US20210388075A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
WO2009033027A3 (en) Suppression of scn9a gene expression and/or function for the treatment of pain
WO2008011083A3 (en) Compounds for enhancing arginase activity and methods of use thereof
EP2698166A3 (en) Complement inhibition for improved nerve regeneration
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
WO2006102596A3 (en) Dosage regimen for the treatment of a traumatic brain injury with progesterone
WO2004022156A3 (en) Methods for treating central nervous system damage
WO2007150064A3 (en) METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF β-GLUCOCEREBROSIDASE
CY1114815T1 (el) Χορηγηση θεραπευτικων χημικων ενωσεων στον εγκεφαλο και σε αλλους ιστους
UA85055C2 (ru) Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний
WO2006116458A3 (en) Modified oligoribonucleotide analogs with enhances immunostimulatory activity
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
MX2010003548A (es) Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida.
WO2008083204A3 (en) Modulation of neurogenesis by melatoninergic ligands
WO2009114089A3 (en) Using fullerenes to enhance and stimulate hair growth
DE60333857D1 (de) Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
WO2004103299A8 (en) Compositions and methods for the treatment of cns injuries
MX2022015818A (es) Uso de moléculas de unión del ligando 13 de quimiocina del motivo c-x-c (cxcl13) para el tratamiento de lesión de nervios periféricos.
ATE533501T1 (de) Verwendung des ped-faktors zur induktion von zellregenerierung
TR200001471T2 (tr) Sinir hücrelerine ait yozlaşmanın engellenmesi için ve sinir hücrelerinin yenilenmesinin oluşması için yerine geçen aminometil-kromansın kullanılması.
WO2007053580A3 (en) Sigma ligands for neuronal regeneration and functional recovery
WO2015165948A3 (en) Compositions for the treatment of diabetic neuropathies
WO2006138316A3 (en) Methods for delivering molecules to the central nervous system
Bayat et al. Effectiveness of an educational intervention on improving health-promoting behaviors and quality of life among health volunteers: Application the BASNEF model
WO2007117440A3 (en) Stimulation of neuron regeneration by secretory leukocyte protease inhibitor
Park et al. The Clinical Research of the Effectiveness of